Healthy, Mild Cognitive Impairment
Conditions
Brief summary
This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.
Detailed description
CROSS-SECTIONAL OBJECTIVES * To measure 18F-RO6958948 retention in selected participants of ALFA-related studies as a function of amyloid levels. * To study the relation between 18F-RO6958948 retention and amyloid levels. * To characterize imaging correlates as a function of tau and amyloid levels. * To study the role of tau retention on cognitive performance. * To define predictors of tau retention. LONGITUDINAL OBJECTIVES * To measure tau accumulation and spreading in participants of the ALFA-related studies of BBRC as a function of baseline amyloid levels. * To study the dynamic relation between tau spreading and amyloid levels longitudinally. * To define predictors of tau spreading.
Interventions
PROCEDUREPositron emission tomography with 18F-RO6958948
tau PET ()
Sponsors
Hoffmann-La Roche
Hospital Clinic of Barcelona
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. To sign the study informed consent form approved by the corresponding authorities. 2. Men and women that have participated in a BBRC-sponsored study, including the ALFA project (STUDY 45-65 FPM/2012), the ALFA+ cohort study (ALFA - FPM - 0311), the ALFA cognition study (ALFAcognition/BBRC2017) or the BarcelonaBeta Dementia Prevention Research Clinic study (BBRC-DemPrev-2018). 3. Participants with an available cerebral MRI within the last 12 months not suggestive of radiological incidental findings constituting an exclusion criterion. 4. Known cognitive status based on the cognitive workup of the BBRC-sponsored studies specified above. Cognitive status should have been determined within the last 12 months. 5. Known AB and tau status. 6. Good knowledge of the language and being literate. 7. Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.
Exclusion criteria
1. Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia and bipolar disorder, as assessed in the BBRC-sponsored studies specified above. 2. Participants with visual and/or hearing impairment. 3. History of encephalitis, ictus or seizures excluding feverish convulsions during childhood, as assessed in the BBRC-sponsored studies specified above. 4. Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumour (metastasis/brain cancer) as verified by MRI. 5. Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study. 6. Clinically relevant renal or hepatic insufficiency. 7. Any other clinically important condition that may jeopardize the study or be dangerous for the participant. 8. Active drug or alcohol abuse, as assessed in the BBRC-sponsored studies specified above. 9. Previous intolerance to PET studies or known hypersensitivity to 18F-RO6958948. 10. Being pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of cerebral tau positivity | at inclusion | Prevalence of cerebral tau positivity assessed by 18F-RO6958948 PET |
| tau accumulation and spreading | 2 years | To predictors of tau spreading |
Countries
Spain
Outcome results
None listed